Establishment Labs (NASDAQ:ESTA) Director Sells $2,048,730.75 in Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 33,925 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $60.39, for a total value of $2,048,730.75. Following the completion of the sale, the director owned 1,223,579 shares in the company, valued at $73,891,935.81. The trade was a 2.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Establishment Labs Stock Down 2.4%

ESTA stock traded down $1.44 on Tuesday, reaching $58.17. 463,235 shares of the company traded hands, compared to its average volume of 523,211. The firm has a fifty day simple moving average of $69.61 and a 200-day simple moving average of $61.66. The company has a market cap of $1.71 billion, a P/E ratio of -33.10 and a beta of 0.91. Establishment Labs Holdings Inc. has a one year low of $26.56 and a one year high of $83.31. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The business had revenue of $64.62 million for the quarter, compared to the consensus estimate of $63.80 million. During the same period in the previous year, the company posted ($1.19) earnings per share. The company’s revenue for the quarter was up 45.2% compared to the same quarter last year. Research analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Hedge Funds Weigh In On Establishment Labs

Several hedge funds and other institutional investors have recently modified their holdings of the company. Simplify Asset Management Inc. bought a new position in Establishment Labs in the 3rd quarter worth $1,555,000. Tejara Capital Ltd grew its holdings in Establishment Labs by 31.2% during the third quarter. Tejara Capital Ltd now owns 102,494 shares of the company’s stock valued at $4,201,000 after purchasing an additional 24,386 shares during the period. Woodson Capital Management LP increased its position in Establishment Labs by 113.3% in the third quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock worth $19,675,000 after buying an additional 255,000 shares in the last quarter. Hood River Capital Management LLC increased its position in Establishment Labs by 138.2% in the second quarter. Hood River Capital Management LLC now owns 53,124 shares of the company’s stock worth $2,269,000 after buying an additional 30,825 shares in the last quarter. Finally, Affinity Asset Advisors LLC raised its stake in shares of Establishment Labs by 19.6% in the second quarter. Affinity Asset Advisors LLC now owns 334,863 shares of the company’s stock worth $14,302,000 after buying an additional 54,863 shares during the period. 72.91% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on ESTA shares. Stephens raised their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Citigroup dropped their target price on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 11th. JPMorgan Chase & Co. raised their price target on shares of Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. BTIG Research boosted their price objective on shares of Establishment Labs from $86.00 to $88.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Finally, Wall Street Zen raised Establishment Labs from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Establishment Labs currently has an average rating of “Moderate Buy” and a consensus target price of $86.86.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.